Andrew Callos Sells 10,000 Shares of Cytokinetics (NASDAQ:CYTK) Stock

Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Andrew Callos sold 10,000 shares of Cytokinetics stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $70.24, for a total value of $702,400.00. Following the sale, the executive vice president directly owned 58,555 shares of the company’s stock, valued at $4,112,903.20. This trade represents a 14.59% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Andrew Callos also recently made the following trade(s):

• On Thursday, July 30th, Andrew Callos sold 14,000 shares of Cytokinetics stock. The stock was sold at an average price of $79.88, for a total transaction of $1,118,320.00.
• On Wednesday, July 1st, Andrew Callos sold 15,000 shares of Cytokinetics stock. The stock was sold at an average price of $85.80, for a total transaction of $1,287,000.00.

Cytokinetics Trading Up 0.7%

CYTK opened at $71.40 on Wednesday. Cytokinetics, Incorporated has a 12-month low of $44.91 and a 12-month high of $88.31. The firm has a 50 day moving average of $79.78 and a two-hundred day moving average of $72.36. The firm has a market capitalization of $8.88 billion, a PE ratio of -9.89 and a beta of 0.36.

Cytokinetics (NASDAQ:CYTK) last released its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($1.50) EPS for the quarter, beating the consensus estimate of ($1.63) by $0.13. The business had revenue of $28.62 million during the quarter, compared to analysts’ expectations of $17.59 million. The firm’s revenue was down 57.1% on a year-over-year basis. During the same period last year, the company earned ($1.12) earnings per share. As a group, analysts predict that Cytokinetics, Incorporated will post -6 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Stifel Nicolaus lifted their price objective on Cytokinetics from $98.00 to $108.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. Citizens Jmp upped their target price on Cytokinetics from $105.00 to $110.00 and gave the stock a “market outperform” rating in a research note on Friday, August 7th. JPMorgan Chase & Co. raised their target price on Cytokinetics from $97.00 to $103.00 and gave the stock an “overweight” rating in a report on Thursday, August 13th. Wells Fargo & Company lifted their price target on Cytokinetics from $95.00 to $105.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. Finally, Royal Bank Of Canada decreased their price target on Cytokinetics from $117.00 to $112.00 and set an “outperform” rating for the company in a report on Friday, August 7th. Nineteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $102.20.

Cytokinetics News Summary

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Cytokinetics reached a Phase 3 milestone in non-obstructive hypertrophic cardiomyopathy (HCM), highlighting progress in its cardiovascular pipeline and potentially expanding the opportunity for its muscle-directed therapies. Cytokinetics Reaches a Phase 3 First in Non-Obstructive HCM
• Positive Sentiment: The company presented new Phase 3 data, prompting continued discussion of the pipeline’s value; one analysis characterized CYTK as approximately 34% undervalued. Cytokinetics Presents New Phase 3 Data
• Positive Sentiment: HC Wainwright reaffirmed its “Buy” rating and set a $140 price target, implying substantial upside from the stock’s recent level. The broader analyst consensus remains “Moderate Buy,” with a target near $102.20.
• Neutral Sentiment: Recent quarterly results exceeded expectations, with a loss of $1.50 per share versus the expected $1.63 loss and revenue of $28.62 million versus a $17.59 million estimate. However, revenue declined 57.1% year over year and the company remains unprofitable.
• Negative Sentiment: CEO Robert Blum sold 7,500 shares for approximately $526,800, EVP Andrew Callos sold 10,000 shares for about $702,400, and director B. Lynne Parshall sold 5,000 shares for roughly $357,400. All trades were conducted under pre-arranged Rule 10b5-1 plans, reducing their value as signals of current management sentiment, though the sales may still weigh modestly on investor confidence. Cytokinetics Insider Trading Activity
• Negative Sentiment: Wall Street Zen lowered its rating on CYTK, providing a counterpoint to the more optimistic sell-side outlook.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CYTK. Kemnay Advisory Services Inc. purchased a new stake in shares of Cytokinetics during the 4th quarter worth about $27,000. Kestra Advisory Services LLC purchased a new position in shares of Cytokinetics in the 4th quarter valued at about $29,000. Northwestern Mutual Wealth Management Co. increased its stake in shares of Cytokinetics by 46.0% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 543 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 171 shares in the last quarter. Quarry LP acquired a new position in Cytokinetics in the 3rd quarter worth about $30,000. Finally, Advisory Services Network LLC acquired a new position in Cytokinetics in the 3rd quarter worth about $32,000.

Cytokinetics Company Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.